GZR102 vs HR17031

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Type 2 Diabetes

Shared mechanism: Insulin receptor / GLP-1 receptor (combination) · full Type 2 Diabetes pipeline

GZR102

Developed by Gan & Lee Pharmaceuticals

Phase 2 in Type 2 Diabetespeptide
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

No aligned efficacy figure on record for this race.

HR17031

Developed by Jiangsu Hengrui Pharmaceuticals

Phase 3 in Type 2 Diabetespeptide
Partial signal

NCT06881264 · Phase 3 · completed

The randomized Phase 3 trial enrolled 401 adults with type 2 diabetes uncontrolled on oral drugs, with HbA1c change at week 26 as the primary endpoint against insulin glargine. The sponsor reports that HR17031 was superior (-1.85% vs -1.06%); the registry has no posted results.

Caveat: this result is taken from a company announcement, not from the trial registry or a peer-reviewed publication. Treat it as the sponsor's own statement.

Reported efficacy

Change in HbA1c: Changes in HbA1c from baseline to week 26: Week 26 HbA1c change, LS mean: HR17031 -1.85% vs insulin glargine -1.06% (sponsor-reported) (met)

Result source: NCT06881264

Results for Type 2 Diabetes

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointGZR102HR17031
HbA1c, change—Not reported—Not posted · NCT06871761
Body weight, change (kg)—Not reported—Not posted · NCT06871761
HbA1c below 7%—Not reported—Not posted · NCT06871761
Fasting plasma glucose, change—Not reported—Not posted · NCT06871761
3-point MACE (% with event)—Not reported—Not posted · NCT06871761

HbA1c, change

GZR102
—Not reported
HR17031
—Not posted · NCT06871761

Body weight, change (kg)

GZR102
—Not reported
HR17031
—Not posted · NCT06871761

HbA1c below 7%

GZR102
—Not reported
HR17031
—Not posted · NCT06871761

Fasting plasma glucose, change

GZR102
—Not reported
HR17031
—Not posted · NCT06871761

3-point MACE (% with event)

GZR102
—Not reported
HR17031
—Not posted · NCT06871761
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

GZR102: no structured comparison results are available for Type 2 Diabetes.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

HR17031
Week 26 HbA1c change, LS mean: HR17031 -1.85% vs insulin glargine -1.06% (sponsor-reported) NCT06881264 · Phase 3 · design grade: moderate · publication or press release
HbA1c change from baseline at week 26: HR17031 -1.53% vs insulin glargine -0.25%; LS-mean difference -1.29% (95% CI -1.48 to -1.10), P<0.0001 (sponsor-reported, ADA 2026) NCT06871761 · Phase 3 · design grade: moderate · reviewed ClinicalTrials.gov result

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: GZR102's landscape · HR17031's landscape